Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Hepatocellular × ribociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 86 Neoplasms 11 Neoplasm Metastasis 10 Glioma 8 Ovarian Neoplasms 6 Melanoma 6 Glioblastoma 6 Squamous Cell Carcinoma of Head and Neck 5 Liposarcoma 5 Carcinoma, Non-Small-Cell Lung 5 Sarcoma 4 Recurrence 4 Medulloblastoma 4 Endometrial Neoplasms 4 Diffuse Intrinsic Pontine Glioma 4 Colorectal Neoplasms 4 Brain Neoplasms 4 Neuroblastoma 3 Neoplasms by Site 3 Lymphoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Diseases 3 Astrocytoma 3 Triple Negative Breast Neoplasms 2 Rhabdoid Tumor 2 Prostatic Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Multiple Endocrine Neoplasia Type 1 2 Meningioma 2

Interventions

Sorafenib 202 lenvatinib 128 Bevacizumab 123 Nivolumab 84 pembrolizumab 73 atezolizumab 71 Radiosurgery 71 durvalumab 63 Oxaliplatin 59 sintilimab 55 Fluorouracil 54 Doxorubicin 44 tislelizumab 42 apatinib 42 Leucovorin 40 tremelimumab 37 Radiofrequency Ablation 37 camrelizumab 36 Radiotherapy 36 Magnetic Resonance Spectroscopy 32 Capecitabine 30 regorafenib 29 Folfox protocol 28 Cisplatin 28 Hepatectomy 26 Gemcitabine 26 Cyclophosphamide 26 cabozantinib 25 Ipilimumab 25 toripalimab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02524119 2021-02-01

LEE001

University of Texas Southwestern Medical Center

Phase 2 Terminated

5 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡